Nyxoah to Release First Quarter 2025 Financial Results on May 14, 2025
Nyxoah (Nasdaq/Euronext: NYXH), a company focused on developing innovative neuromodulation treatments for Obstructive Sleep Apnea (OSA), has scheduled its Q1 2025 financial results release for May 14, 2025. The company will host a conference call with management on the same day at 2:00pm CET / 8:00am ET.
Investors and analysts can access the earnings call through the company's Investor Relations webpage or via webcast link. Those planning to ask questions during the call should register at least 10 minutes before the start time using a separate registration link. A replay of the webcast will be available shortly after the call concludes.
Nyxoah (Nasdaq/Euronext: NYXH), un'azienda specializzata nello sviluppo di trattamenti innovativi di neuromodulazione per l'Apnea Ostruttiva del Sonno (OSA), ha programmato la pubblicazione dei risultati finanziari del primo trimestre 2025 per il 14 maggio 2025. La società terrà una conference call con il management lo stesso giorno alle 14:00 CET / 8:00 ET.
Investitori e analisti potranno seguire la chiamata tramite la pagina delle Relazioni con gli Investitori dell'azienda o tramite un link webcast. Chi desidera porre domande durante la call deve registrarsi almeno 10 minuti prima dell'inizio utilizzando un link di registrazione separato. Una registrazione della webcast sarà disponibile poco dopo la conclusione della chiamata.
Nyxoah (Nasdaq/Euronext: NYXH), una empresa dedicada al desarrollo de tratamientos innovadores de neuromodulación para la Apnea Obstructiva del Sueño (OSA), ha programado la publicación de sus resultados financieros del primer trimestre de 2025 para el 14 de mayo de 2025. La compañía realizará una conferencia telefónica con la dirección ese mismo día a las 14:00 CET / 8:00 ET.
Inversores y analistas podrán acceder a la llamada de resultados a través de la página de Relaciones con Inversores de la empresa o mediante un enlace webcast. Quienes deseen hacer preguntas durante la llamada deben registrarse al menos 10 minutos antes del inicio usando un enlace de registro separado. Una grabación del webcast estará disponible poco después de la conclusión de la llamada.
Nyxoah(나스닥/유로넥스트: NYXH)는 폐쇄성 수면 무호흡증(OSA)을 위한 혁신적인 신경조절 치료법 개발에 주력하는 회사로, 2025년 1분기 재무실적 발표를 2025년 5월 14일로 예정했습니다. 회사는 같은 날 오후 2시 CET / 오전 8시 ET에 경영진과의 컨퍼런스 콜을 개최할 예정입니다.
투자자와 애널리스트는 회사의 투자자 관계 웹페이지나 웹캐스트 링크를 통해 실적 발표 콜에 접속할 수 있습니다. 콜 중 질문을 하려는 분들은 시작 10분 전까지 별도의 등록 링크를 통해 등록해야 합니다. 웹캐스트 녹화는 콜 종료 직후에 제공될 예정입니다.
Nyxoah (Nasdaq/Euronext : NYXH), une entreprise spécialisée dans le développement de traitements innovants de neuromodulation pour l'Apnée Obstructive du Sommeil (AOS), a prévu la publication de ses résultats financiers du premier trimestre 2025 pour le 14 mai 2025. La société tiendra une conférence téléphonique avec la direction le même jour à 14h00 CET / 8h00 ET.
Les investisseurs et analystes pourront accéder à la conférence téléphonique via la page Relations Investisseurs de l'entreprise ou via un lien webcast. Ceux qui souhaitent poser des questions durant l'appel doivent s'inscrire au moins 10 minutes avant le début en utilisant un lien d'inscription distinct. Une rediffusion du webcast sera disponible peu après la fin de l'appel.
Nyxoah (Nasdaq/Euronext: NYXH), ein Unternehmen, das sich auf die Entwicklung innovativer Neuromodulationsbehandlungen für obstruktive Schlafapnoe (OSA) spezialisiert hat, hat die Veröffentlichung der Finanzergebnisse für Q1 2025 für den 14. Mai 2025 geplant. Am selben Tag wird das Management eine Telefonkonferenz um 14:00 Uhr CET / 8:00 Uhr ET abhalten.
Investoren und Analysten können an der Ergebnispräsentation über die Investor-Relations-Webseite des Unternehmens oder über einen Webcast-Link teilnehmen. Wer während der Konferenz Fragen stellen möchte, sollte sich mindestens 10 Minuten vor Beginn über einen separaten Registrierungslink anmelden. Eine Aufzeichnung des Webcasts wird kurz nach Ende der Konferenz zur Verfügung stehen.
- None.
- None.
Nyxoah to Release First Quarter 2025 Financial Results on May 14, 2025
Mont-Saint-Guibert, Belgium – Wednesday May 7, 2025, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company will release financial results for the first quarter of 2025 on Wednesday, May 14, 2025. Company management will host a conference call to discuss financial results that day beginning 2:00pm CET / 8:00am ET.
A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or through this link: Nyxoah's Q1 2025 Earnings Call Webcast. For those not planning to ask a question of management, the Company recommends listening via the webcast.
If you plan to ask a question, please use the following link: Nyxoah's Q1 2025 Earnings Call. After registering, an email will be sent, including dial-in details and a unique conference call access code required to join the live call. To ensure you are connected prior to the beginning of the call, the Company suggests registering a minimum of 10 minutes before the start of the call.
The archived webcast will be available for replay shortly after the close of the call.
About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.
Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study.
For more information, please visit http://www.nyxoah.com/.
Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States
FORWARD-LOOKING STATEMENTS
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company’s or, as appropriate, the Company directors’ or managements’ current expectations regarding the Genio® system; planned and ongoing clinical studies of the Genio® system; the potential advantages of the Genio® system; Nyxoah’s goals with respect to the development, regulatory pathway and potential use of the Genio® system; receipt of FDA approval; satisfactory completion of a manufacturing facilities, methods and controls review, and the anticipated timing of the foregoing; entrance to the U.S. market; and the Company's results of operations, financial condition, liquidity, performance, prospects, growth and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2024, filed with the Securities and Exchange Commission (“SEC”) on March 20, 2025, and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward- looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.
Contacts: Nyxoah
John Landry, CFO
IR@nyxoah.com
For Media
In United States
FINN Partners – Alyssa Paldo alyssa.paldo@finnpartners.com
In International/Germany
MC Services – Anne Hennecke nyxoah@mc-services.eu
In Belgium/France
Backstage Communication – Gunther De Backer gunther@backstagecom.be
Attachment
FAQ
When will Nyxoah (NYXH) release its Q1 2025 earnings?
What time is Nyxoah's Q1 2025 earnings call?
How can I access Nyxoah's Q1 2025 earnings call?
What does Nyxoah (NYXH) company do?
